Mounjaro Wegovy Weight Loss Weight Management

Jun 25, 2026
15 MIN READ

What Is Better for Weight Loss: Mounjaro or Wegovy?

Both Mounjaro and Wegovy are GLP-1 receptor agonists used for weight loss, but they work through different mechanisms and show distinct clinical results. Understanding their differences helps you make an informed choice about your treatment.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 25, 2026
15 MIN READ

what is better for weight loss: mounjaro or wegovy? — PlexusDx GLP-1 education

Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both injectable medications that help people lose weight, but they activate different hormone pathways in your body. Tirzepatide targets two receptors—GLP-1 and GIP—while semaglutide focuses only on GLP-1 signaling. Clinical trials show tirzepatide users lost slightly more weight on average than semaglutide users over the same timeframe.

How Mounjaro and Wegovy Work Differently

Wegovy contains semaglutide, a single-receptor medication that mimics glucagon-like peptide-1 (GLP-1), a natural hormone that reduces hunger and slows digestion. Mounjaro contains tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. This dual-receptor approach may produce stronger appetite suppression and better blood sugar control in some patients.

The difference in mechanism explains why individual responses vary widely. Some patients experience excellent results with semaglutide alone, while others need dual-receptor activation to reach their weight loss goals. Your genetic makeup influences how effectively each medication works for you—a factor that precision testing can reveal before starting treatment.

Clinical Trial Results: Weight Loss Outcomes

In head-to-head studies, tirzepatide users lost between 20% and 22% of their starting body weight over 68 weeks of treatment, compared to 16% to 18% weight loss for semaglutide users at similar timeframes. The SURMOUNT-1 trial showed tirzepatide achieved greater reductions in body weight than semaglutide across multiple dose levels. However, individual results depend on starting weight, metabolism, lifestyle, and genetic factors—some patients achieve their goals faster with semaglutide.

Weight loss typically plateaus after 6 to 12 months on either medication, though continuing treatment maintains the loss. Starting dose, dose escalation schedule, and adherence all influence final outcomes. Neither medication works without dietary changes and increased physical activity, which remain the foundation of successful weight management.

Side Effects and Tolerability Comparison

Both medications commonly cause nausea, vomiting, diarrhea, and constipation—side effects that usually decrease over weeks to months as your body adjusts. Tirzepatide users report slightly higher rates of gastrointestinal side effects in clinical trials, though most are mild to moderate and manageable with slower dose increases. Starting at a low dose and increasing gradually every 4 weeks helps minimize nausea and allows your digestive system to adapt.

Serious side effects are rare with both medications when used as prescribed. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should avoid these medications. Pregnancy is not recommended during treatment with either drug. Your prescribing provider reviews your full medical history to ensure safety before starting therapy.

Cost and Access: Mounjaro vs Wegovy at PlexusDx

PlexusDx offers compounded tirzepatide injection starting at $249 per month and compounded semaglutide injection starting at $149 per month—flat pricing that does not change as your dose increases. Both are dispensed from licensed 503A compounding pharmacies and available in all 50 states without insurance requirements or membership fees. HSA and FSA accounts cover both medications, reducing out-of-pocket costs for eligible patients.

The lower starting price of semaglutide makes it an accessible first-line option for budget-conscious patients, while tirzepatide's slightly higher cost may be justified by stronger weight loss results in some individuals. PlexusDx also offers oral versions of both medications (oral semaglutide at $249/mo and oral tirzepatide at $279/mo) for patients who prefer tablets to injections. Your choice depends on your weight loss goals, response patterns, and financial situation—not on assumptions about which drug is universally 'better.'

Genetic Testing for Personalized GLP-1 Selection

PlexusDx Precision Peptide Genetic Test analyzes how your DNA influences your response to both GLP-1 and GIP receptor medications. The test identifies key variants in genes like GLP1R (rs6923761), GIPR (rs1800437), and MC4R (rs17782313) that predict how strongly your body responds to semaglutide or tirzepatide. Knowing your genetic predisposition helps your provider select the medication most likely to work for your unique biology.

This 49-peptide, 14-pathway analysis costs just $99 after your first month of treatment and removes guesswork from therapy selection. Some patients discover through genetic insights that they are naturally responsive to GLP-1 monotherapy and will succeed on semaglutide, while others have genetic patterns suggesting dual-receptor activation will produce better results. Testing transforms weight loss from trial-and-error into precision medicine.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication should I choose: Mounjaro or Wegovy?

The best choice depends on your weight loss goals, side effect tolerance, budget, and genetic response patterns. Tirzepatide typically produces larger weight losses in clinical trials, but semaglutide works excellently for many patients at a lower starting price. PlexusDx recommends genetic testing after your first month to personalize your choice based on your unique peptide pathways.

Does tirzepatide cause more side effects than semaglutide?

Tirzepatide users report slightly higher rates of nausea and gastrointestinal symptoms in studies, but most side effects are mild and improve within weeks. Starting at a low dose and increasing gradually every 4 weeks minimizes discomfort for both medications. Your provider can adjust your dosing schedule if side effects become bothersome.

Can I switch from Wegovy to Mounjaro if I'm not losing weight?

Yes, switching between medications is safe and often effective when one drug isn't producing desired results. PlexusDx supports medication switches, and your provider can discuss the timing and transition protocol with you. Genetic testing can inform whether switching makes sense based on your peptide pathway patterns.

How much does compounded tirzepatide or semaglutide cost at PlexusDx?

Compounded semaglutide injection starts at $149 per month, and compounded tirzepatide injection starts at $249 per month—with pricing that stays flat as your dose increases. Both are available in all 50 states without insurance, and HSA/FSA accounts are accepted. Oral versions are also available at slightly higher prices if you prefer tablets.

What can PlexusDx Precision Peptide Genetic Test tell me about my medication response?

The test analyzes 49 peptides across 14 metabolic pathways, including variants in GLP1R, GIPR, FTO, and MC4R genes that predict how well you'll respond to semaglutide, tirzepatide, or combination therapies. For just $99 after your first treatment month, you gain 150+ genetic insights that help PlexusDx optimize your medication choice and dosing strategy for maximum results.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves